-
Most Voters Believe the Midterm Elections Will Be Accurate, Poll Finds
But about half expressed concerns that Republicans could try to overturn the results, a New York Times/Siena poll found.
-
Does Congress Need to Approve the Arch? Trump Says It Did 100 Years Ago.
The administration says the arch fulfills the “historic design intent” of a proposal from the 1920s. But does it honor history or flout it?
-
Trump Administration Asks Appeals Court to Intervene in California Mail Ballot Suit
The Justice Department sought to jump-start a lawsuit aimed at compelling the state to not count as many as 20,000 mail ballots it claims were sent to noncitizens.
-
Video by Left-Wing Group Claims Lindsey Graham Paid Men for Sex
Progressive activists released a video of three men making the allegations about the South Carolina Republican, who died in July. The New York Times has not confirmed their claims.
-
Pete Ricketts’s Wealth Puts Class at the Center of Nebraska’s Senate Race
In a year when the wealth of the rich soared while workers lost ground to inflation, class has become political, especially in the Nebraska Senate race.
-
Unveiling Cosmic Mysteries: How the Universe Continues to Surprise Us
Unveiling Cosmic Mysteries: How the Universe Continues to Surprise Us There’s something deeply humbling about staring into the night sky. I remember lying on the grass during summer nights as a child, eyes wide open, trying to count stars. Back then, the universe felt like an endless sea of wonder, a vastness I could never…
-
When Most of the Price is Contingent: Questions for Life Sciences Sellers
In many life sciences sales, especially of earlier-stage companies, the buyer pays a modest amount at closing. The rest comes only if the asset succeeds, through development, regulatory and sales milestones, and sometimes through royalties on future sales. How much of the headline value is contingent varies widely. In the life sciences sales I have…
-
OCC Releases Yearlong Debanking Review, CFPB Opens Parallel Investigation
The Office of the Comptroller of the Currency (OCC) released findings from a yearlong review of nine of the largest national banks it supervises by asset size, covering the period from 2020 through September 2025….By: Cooley LLP
-
UPC upholds pharmaceutical patent for subgroup of patients: Key lessons for patent holders and challengers
On 9 October 2026, the Milan section of the Central Division of the Unified Patent Court (UPC) rejected Biogaran’s revocation action against Lundbeck’s European patent EP 4 223 296 (UPC_CFI_1587/2025)….By: McDermott Will & Schulte
-
Vertex Pharms. Inc. v. Lupin Ltd.
Case Name: Vertex Pharms. Inc. v. Lupin Ltd., No. 22-cv-966-SB, 2026 WL 2474714 (D. Del. Aug. 24, 2026) (Bibas, J.) Drug Product and Patent(s)-in-Suit: Kalydeco® (ivacaftor); U.S. Patent Nos. 10,646,481 (“the ’481 patent”), 11,564,916 (“the ’916 patent”), 12,458,635 (“the ’635 patent”), and 10,272,046 (“the ’046 patent”)…By: Robins Kaplan LLP
